
Immunotherapy is a type of treatment that uses the body's own immune system to fight diseases, including cancer. One of the key players in immunotherapy is antibodies.
Antibodies, also known as immunoglobulins, are proteins produced by B-cells that play a critical role in the immune system. They are responsible for identifying and neutralizing foreign substances, such as bacteria and viruses, by binding to them and marking them for destruction by other immune cells.
In recent years, researchers have discovered that antibodies can also be used to target cancer cells. Antibody-based immunotherapies work by using monoclonal antibodies, which are antibodies that are made in the laboratory to target specific proteins on cancer cells. When the monoclonal antibodies bind to the cancer cells, they can trigger an immune response that leads to the destruction of the cancer cells.
At Biointron, we are dedicated to accelerating antibody discovery for the development of new immunotherapies. Our expertise in antibody screening, engineering, and production allows us to provide high-quality antibody services that are critical to the success of immunotherapy research. Learn more about our CHO-K1 stable cell line generation service and how it supports cutting-edge antibody production. For foundational solutions, explore our CHOK1BN cell line commercial license to ensure precision in antibody development.
Through our state-of-the-art manufacturing and automation process, we are able to deliver antibody products that meet international standards in terms of quality, purity, and potency. By working with us, our clients can rest assured that they are receiving the highest quality antibodies for their research and development needs.
As the field of immunotherapy continues to grow and evolve, we are committed to staying at the forefront of antibody discovery and production. With our expertise and dedication to quality, we are proud to play a key role in the development of new immunotherapies that have the potential to transform the way we treat cancer and other diseases.
In this article, we explore the major trends shaping the future of targeted canc……
Site-specific conjugation limits payload attachment to defined positions on the ……
Affinity maturation can improve binding to the intended target, but it can also ……
ADC development is no longer limited to the antibody-linker-toxin model. The fie……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



